Accelerating drug development by early unwanted immunogenicity testing

Recorded webinar

Complex immune responses elicited upon treatment with biotherapeutic drugs are now revolutionizing the field of immuno-oncology. However, unwanted immune responses exerted by biologics can result in severe adverse effects. Immunogenicity testing at the early phase of drug development therefore can play a crucial role to avoid possible clinical consequences of anti-drug antibody (ADA) responses. Testing unwanted immune responses during drug development is becoming increasingly important for pharmaceutical industries and regulatory agencies like the FDA and EMEA.  

This webinar covers:  

  • Causes and consequences of unwanted immunogenicity
  • In vitro cellular assays to assess unwanted immunogenicity, including T cell activation/proliferation and MAPPS (MHC-associated peptide proteomics) assays
  • Strategies to manage and reduce unwanted immune responses
video preview Play video

MACS Academy: Immunogenicity testing – drug development

Watch the webinar to learn about immunogenicity testing at the early phase of drug development. Find out how it can play a crucial role in avoiding possible clinical consequences of unwanted immune responses.

Sofie Pattijn, Ph.D., CTO at ImmunXperts SA, a service provider for drug development processes

Discover related products

More questions about predicitve immunogenicity? Contact us by filling in the form below.

Contact us

General Information

Detailed Information

Please give your details for further inquiries.

* Mandatory field

Questions / Comments